Acrivon Therapeutics, Inc. Common Stock
ACRV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$80,556 | -$60,388 | -$31,167 | -$16,243 |
| Dep. & Amort. | $1,006 | $536 | $364 | $37 |
| Deferred Tax | $0 | -$3,609 | $0 | $0 |
| Stock-Based Comp. | $14,288 | $11,618 | $2,185 | $497 |
| Change in WC | $2,438 | $8,138 | -$1,532 | $328 |
| Other Non-Cash | -$2,845 | $1,064 | $33 | $1,399 |
| Operating Cash Flow | -$65,669 | -$42,641 | -$30,117 | -$13,982 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$2,768 | -$1,288 | -$2,166 | -$238 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$202,926 | -$56,528 | -$150,178 | $0 |
| Inv. Sales/Matur. | $153,923 | $108,533 | $10,668 | $0 |
| Other Inv. Act. | $0 | $0 | $0 | $0 |
| Investing Cash Flow | -$51,771 | $50,717 | -$141,676 | -$238 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $69,997 | -$257 | $104,458 | $0 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $51,030 | -$1,297 | -$2,749 | $112,221 |
| Financing Cash Flow | $121,027 | -$1,554 | $101,709 | $112,221 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $3,587 | $6,522 | -$70,084 | $98,001 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $36,429 | $29,907 | $99,991 | $1,990 |
| End Cash | $40,016 | $36,429 | $29,907 | $99,991 |
| Free Cash Flow | -$68,437 | -$43,929 | -$32,283 | -$14,220 |